Alternatives to Amiodarone

1. Dronedarone (Class I-IV mixed)

• Structurally similar to amiodarone but lacks the iodine moiety, reducing thyroid and pulmonary toxicity.
• Shares properties with Vaughan Williams Classes I, II, III, and IV.
• More effective than placebo but less effective than amiodarone for maintaining sinus rhythm after cardioversion.
• Low incidence of proarrhythmia and organ toxicity compared to amiodarone.
• Approved for AF/atrial flutter in patients with paroxysmal or persistent AF who have converted to sinus rhythm.
• Contraindicated in: advanced heart failure (trend toward increased mortality), permanent AF, severe hepatic dysfunction.
• Can be used in renal dysfunction.
• Washington Manual of Medical Therapeutics, p. 249

2. Sotalol (Class II + III)

• Combined beta-blocker + potassium channel blocker (prolongs QT and action potential).
• Effective for AF, atrial flutter, and ventricular tachycardia.
• Reverse-use dependence: QT prolongation is worse at slower heart rates, increasing torsades de pointes (TdP) risk.
• Must be initiated in a monitored inpatient setting.
• Renal dose adjustment required (primarily renally excreted).
• Appropriate for coronary artery disease patients; avoid in advanced HF.
• Washington Manual of Medical Therapeutics, p. 248; Fuster and Hurst's The Heart, 15th Ed, p. 1145

3. Flecainide (Class IC)

• Sodium channel blocker - slows conduction velocity.
• Highly effective for AF/SVT and maintaining sinus rhythm.
• Only used in structurally normal hearts - can be pro-arrhythmic in ischemic heart disease or LV dysfunction (CAST trial data).
• Often used as "pill-in-the-pocket" for paroxysmal AF.
• Avoid in: coronary artery disease, heart failure, significant LV hypertrophy.
• Fuster and Hurst's The Heart, 15th Ed, p. 1145

4. Propafenone (Class IC)

• Sodium channel blocker with mild beta-blocking properties.
• Similar efficacy and indications to flecainide.
• Restricted to structurally normal hearts for the same reasons as flecainide.
• Metabolized hepatically; CYP2D6 involvement - drug interactions relevant.
• Fuster and Hurst's The Heart, 15th Ed, p. 1145

5. Dofetilide (Class III - pure)

• Pure potassium channel (IKr) blocker - no Class I/II/IV effects.
• Effective for AF/flutter cardioversion and maintenance of sinus rhythm.
• Neutral mortality effect in LV dysfunction - one of only two drugs proven safe in heart failure (the other is amiodarone).
• Mandatory inpatient initiation for 72 hours with QTc monitoring after each dose.
• Contraindicated if baseline QTc >440 ms (or >500 ms with BBB).
• Multiple drug-drug interactions (verapamil, cimetidine, trimethoprim are contraindicated - they block renal secretion of dofetilide).
• Washington Manual, p. 248; Fuster and Hurst's The Heart, 15th Ed, p. 1145

6. Ibutilide (Class III)

• IV formulation only - used for acute cardioversion of AF/atrial flutter.
• Risk of TdP (~4%) - requires monitoring after administration.
• Not for long-term maintenance.

7. Lidocaine (Class IB)

• IV alternative for ventricular fibrillation/pulseless VT when amiodarone is unavailable in cardiac arrest.
• No more effective than amiodarone in cardiac arrest but has fewer side effects.
• Short-term use only; no oral formulation for chronic management.
• Miller's Anesthesia, 10th Ed; Barash Clinical Anesthesia, 9th Ed

Choosing the Right Alternative - Key Decision Framework